AssetMark Inc’s Crinetics Pharmaceuticals CRNX Stock Holding History

AssetMark Inc’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$609K	Sell	16,284 -8	-0%	-$297	﹤0.01%	1190
2026 Q1	$592K	Sell	16,292 -1,673	-9%	-$74.7K	﹤0.01%	1135
2025 Q4	$836K	Sell	17,965 -872	-5%	-$38.8K	﹤0.01%	1053
2025 Q3	$785K	Buy	18,837 +170	+0.9%	+$5.44K	﹤0.01%	1016
2025 Q2	$537K	Buy	18,667 +603	+3%	+$18.6K	﹤0.01%	1034
2025 Q1	$606K	Sell	18,064 -97	-0.5%	-$3.62K	﹤0.01%	950
2024 Q4	$929K	Buy	18,161 +1,014	+6%	+$56.7K	﹤0.01%	865
2024 Q3	$876K	Buy	17,147 +2,030	+13%	+$105K	﹤0.01%	807
2024 Q2	$677K	Buy	15,117 +4,331	+40%	+$200K	﹤0.01%	831
2024 Q1	$505K	Buy	+10,786	New	+$422K	﹤0.01%	829

Other funds holding CRNX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

LAM

Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return

AssetMark Inc's CRNX Position: Q2 2026 in Review

AssetMark Inc reduced its Crinetics Pharmaceuticals (CRNX) stake by 0.05% in Q2 2026, selling an estimated $297 and leaving 16,284 shares worth $609K. The position accounts for ﹤0.01% of the portfolio, ranked #1190.

AssetMark Inc first reported a position in CRNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $929K in Q4 2024. 52 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

AssetMark Inc held 16,284 shares of Crinetics Pharmaceuticals worth $609K as of Q2 2026.
AssetMark Inc sold 8 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $297.
Crinetics Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1190 holding.
AssetMark Inc first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
AssetMark Inc's Crinetics Pharmaceuticals position peaked at $929K in Q4 2024.
52 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.